deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02040857

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma

Sponsor: Dana-Farber Cancer Institute

Conditions Breast Cancer
Interventions Aromatase Inhibitor Palbociclib
Updated 13 times since 2017 Last updated: Apr 23, 2025 Started: Jan 31, 2014 Primary completion: May 31, 2018 Completion: Dec 27, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02040857, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Dana-Farber Cancer Institute, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2019 · 15 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Jan 2024 · 21 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – present · 14 months · monthly snapshot

Change History

13 versions recorded

  1. May 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — May 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2024 — Mar 2024 [monthly]

    Completed PHASE2

▶ Show 8 earlier versions

  1. Apr 2022 — Jan 2024 [monthly]

    Completed PHASE2

  2. Sep 2021 — Apr 2022 [monthly]

    Completed PHASE2

  3. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Dec 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2018 — Dec 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE2

  7. Feb 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Dana-Farber Cancer Institute
  • Pfizer
Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations